NCT04164199 2026-03-16
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
BeOne Medicines
Phase 3 Enrolling by invitation
Clinical Trials
64 trialsNCT06556563 2026-03-13
EF-41
NovoCure Ltd.
Phase 3 Recruiting
NCT07452458 2026-03-05
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
NRG Oncology
Phase 3 Not yet recruiting
NCT07195591 2026-03-04
BRIDGES
GT Medical Technologies, Inc.
Phase 3 Recruiting
NCT06346067 2026-02-27
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Erasca, Inc.
Phase 3 Active not recruiting
NCT06448286 2026-02-19
PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma
Jonsson Comprehensive Cancer Center
Phase 3 Not yet recruiting
NCT05095376 2026-02-17
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NRG Oncology
Phase 3 Active not recruiting
NCT05331521 2026-02-03
ImproveCodel
University Hospital Heidelberg
Phase 3 Recruiting
NCT06388733 2026-02-03
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
NeuroTrials, LLC
Phase 3 Recruiting
NCT07375563 2026-01-29
NB-NK-2026
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3 Recruiting
NCT05902169 2025-11-10
SONOBIRD
CarThera
Phase 3 Active not recruiting
NCT07215910 2025-10-14
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Not yet recruiting
NCT04919226 2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3 Active not recruiting
NCT00978458 2025-09-08
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT06490536 2025-08-29
The Sagittarius Trial
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 3 Recruiting
NCT03345095 2025-07-01
MIRAGE
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT02667587 2025-06-18
CheckMate548
Bristol-Myers Squibb
Phase 3 Completed
NCT05439278 2025-05-21
Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma
Severance Hospital
Phase 3 Recruiting
NCT06419946 2024-11-19
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
Vastra Gotaland Region
Phase 3 Not yet recruiting
NCT05271240 2024-09-19
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Northwell Health
Phase 3 Recruiting
NCT06477939 2024-06-27
THREE-GLEES
Institut de cancérologie Strasbourg Europe
Phase 3 Not yet recruiting
NCT03776071 2024-04-22
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
Denovo Biopharma LLC
Phase 3 Completed
NCT00626990 2023-09-11
CATNON
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Active not recruiting
NCT00482677 2023-08-22
Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme
Canadian Cancer Trials Group
Phase 3 Completed
NCT04532229 2023-07-27
Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children
Biotech Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT05718466 2023-07-17
Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
Henry Ford Health System
Phase 3 Completed
NCT02573324 2023-05-11
Intellance1
AbbVie
Phase 3 Completed
NCT03495921 2023-04-26
VITA
Gradalis, Inc.
Phase 3 Terminated
NCT02617589 2023-03-28
CheckMate 498
Bristol-Myers Squibb
Phase 3 Completed
NCT02761070 2023-03-08
RE-GEND
Kyorin University
Phase 3 Unknown
NCT05647954 2022-12-13
A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver
Taizhou Hanzhong biomedical co. LTD
Phase 3 Unknown
NCT05600491 2022-10-31
A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme
Sun Yat-sen University
Phase 3 Unknown
NCT03243461 2022-06-06
HIT-HGG-2013
University of Göttingen
Phase 3 Unknown
NCT02288897 2022-01-19
PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Provectus Pharmaceuticals
Phase 3 Terminated
NCT04829097 2021-04-02
Neoadjuvant Temozolomide Combined With Simultaneous IMRT for Treatment of Glioblastoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 3 Unknown
NCT01649830 2020-05-28
Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma
Sun Yat-sen University
Phase 3 Recruiting
NCT00004259 2019-09-12
Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas
Radiation Therapy Oncology Group
Phase 3 Completed
NCT01014767 2019-08-20
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
Tufts Medical Center
Phase 3 Terminated
NCT00884741 2019-07-24
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT03633552 2018-08-16
Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma
Mashhad University of Medical Sciences
Phase 3 Unknown
NCT00096265 2018-03-09
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Terminated
NCT01765088 2018-02-23
A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas
Sun Yat-sen University
Phase 3 Unknown
NCT03435302 2018-02-19
HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma
Peking University Cancer Hospital & Institute
Phase 3 Unknown
NCT01480479 2018-01-16
ACT IV
Celldex Therapeutics
Phase 3 Completed
NCT00943826 2017-09-25
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
Hoffmann-La Roche
Phase 3 Completed
NCT01260103 2017-07-26
Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma
Burzynski Research Institute
Phase 3 Withdrawn
NCT01149109 2017-06-14
CeTeG
University Hospital, Bonn
Phase 3 Completed
NCT00091572 2017-06-06
Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00335075 2017-05-15
Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00916409 2017-04-10
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
NovoCure Ltd.
Phase 3 Completed